SequelSEC

BioCardia, Inc. BCDA

Biological Products, (No Diagnostic Substances) · CIK 0000925741 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$8.28M
Fiscal year ended 2025-12-31
Free cash flow
-$7.44M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$9.70MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.89Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity10.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio1.12x19th

BioCardia, Inc. (BCDA) reported revenue of $0 and net income of -$8.23M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BioCardia, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

BioCardia, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$0$58.00K$477.00K$1.35M$1.02M$145.00K$710.00K$625.00K$479.00K$576.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailable$0$4.00K$358.00K$517.00K$690.00K$746.00K
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable$141.00K$352.00K$108.00K-$211.00K-$170.00K
Operating income-$8.28M-$8.00M-$11.64M-$11.90M-$12.63M-$15.53M-$14.21M-$14.10M-$12.40M-$7.61M
Net income-$8.23M-$7.95M-$11.57M-$11.91M-$12.62M-$15.00M-$14.71M-$13.99M-$12.31M-$10.31M
Research & development$4.96M$4.39M$7.73M$8.83M$8.56M$9.81M$8.56M$8.45M$5.80M$3.33M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$3.32M$3.67M$4.40M$4.42M$5.09M$5.86M$6.00M$5.76M$6.40M$4.11M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BioCardia, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$2.50M$2.37M$1.10M$7.36M$12.87M$21.41M$5.58M$5.36M$12.69M$21.35M
Total assets$3.41M$3.72M$2.99M$9.79M$15.72M$23.42M$7.68M$6.42M$13.54M$22.08M
Current assets$2.73M$2.62M$1.46M$7.86M$13.48M$22.66M$6.38M$6.22M$13.32M$21.92M
Total liabilities$2.52M$2.89M$4.59M$4.90M$5.34M$4.25M$5.31M$2.62M$2.41M$1.50M
Current liabilities$2.43M$2.32M$3.61M$3.58M$3.71M$4.25M$4.00M$2.55M$2.33M$1.44M
Total equity incl. NCI$895.00K$837.00K-$1.60M$4.89M$10.38M$19.18M$2.37M$3.79M$11.12M$20.58M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$4.00K$141.00K$191.00K$135.00K
Accounts receivable$20.00K$0$63.00K$201.00K$147.00K$232.00K$147.00K$274.00K$95.00K$74.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$641.00K$385.00K$890.00K$683.00K$507.00K$746.00K$914.00K$743.00K$902.00K$525.00K

Cash flow

BioCardia, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$7.44M-$7.89M-$9.97M-$10.56M-$10.37M-$12.36M-$9.44M-$11.07M-$8.67M-$5.52M
Capital expenditures$7.00K$6.00K$12.00K$70.00K$116.00K$32.00K$146.00K$66.00K$136.00KUnavailable
Investing cash flow-$7.00K-$6.00K-$12.00K-$70.00K-$116.00K-$32.00K-$146.00K-$66.00K-$136.00K$18.92M
Financing cash flow$7.57M$9.16M$3.73M$5.12M$1.95M$28.21M$9.82M$3.80M$144.00K$4.40M
Net change in cash$125.00K$1.27M-$6.26M-$5.51M-$8.54M$15.82M$227.00KUnavailableUnavailableUnavailable
Stock-based compensation$430.00K$741.00K$1.03M$1.18M$1.66M$2.95M$2.72M$2.77M$2.71M$942.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$24.00K$67.00K$84.00K$82.00K$60.00K$68.00K$111.00K$88.00K$78.00K$39.00K

Derived

BioCardia, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$7.44M-$7.89M-$9.99M-$10.63M-$10.48M-$12.39M-$9.59M-$11.14M-$8.81MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable97.2%49.6%17.3%-44.1%-29.5%
Operating marginUnavailable-13794.8%-2441.1%-880.3%-1244.3%-10709.7%-2001.8%-2256.3%-2589.8%-1320.8%
FCF marginUnavailable-13606.9%-2093.5%-786.3%-1032.7%-8544.1%-1350.8%-1781.6%-1838.6%Unavailable
SBC / revenueUnavailable1277.6%215.9%87.5%163.6%2035.9%383.4%443.8%565.1%163.5%
Current ratio1.12x1.13x0.40x2.19x3.63x5.33x1.59x2.44x5.71x15.18x
Revenue YoY growth-100.0%-87.8%-64.7%33.2%600.0%-79.6%13.6%30.5%-16.8%Unavailable
Net marginUnavailable-13700.0%-2425.8%-880.7%-1243.6%-10347.6%-2071.7%-2237.9%-2569.5%-1789.9%
R&D / revenueUnavailable7563.8%1619.7%653.4%843.2%6764.8%1205.9%1352.5%1210.6%578.1%
CapEx / revenueUnavailable10.3%2.5%5.2%11.4%22.1%20.6%10.6%28.4%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCDA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q/A · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-08-11View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2021-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.